Mode
Text Size
Log in / Sign up
Phase 3 Completed N=25 Basic Science

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

Platelet Dysfunction Due to Drugs
Source: ClinicalTrials.gov NCT04342819 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcomePrimary: P2Y12 Reaction Units — 187.35 P2Y12 Reaction Units
◆ Published Evidence
Emerging
13citations · ~3 / year
The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study.
Cardiology and therapy · 2021 · Open access · Likely link

Summary

The mechanistic effects of empagliflozin on platelet function profiles have not yet been ascertained.

Linked Publications

  • The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study.
    Cardiology and therapy · 2021 · 13 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
P2Y12 Reaction Units
187.35

Eligibility Criteria

Inclusion Criteria

  • between 18 and 74 years of age,
  • have stable coronary artery disease and diabetes mellitus, already on DAPT with aspirin and clopidogrel for at least 6 months,

Exclusion Criteria

  • presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,
  • history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,
  • history of clinical and/or hemodynamic instability,
  • within 1 month of placement of a bare metal stent,
  • within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,
  • planned coronary revascularization,
  • treatment with fibrin-specific fibrinolytic therapy 1.5,
  • body weight 75 years,
  • hemoglobin 2 mg/dL,
  • hepatic enzymes >2.5 times the upper limit of normal,
  • pregnancy and/or lactation.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04342819) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search